Study of Transition, Outcomes, and Gender

From HandWiki
Short description: Cohort study

The Study of Transition, Outcomes, and Gender (STRONG) is a cohort study of health in transgender people before and during or after gender-affirming treatments such as gender-affirming hormone therapy and gender-affirming surgery.[1] It is being conducted at Kaiser Permanente sites in Northern California, Southern California, and Georgia and includes over 6,000 transgender people.[1] The study was underway by 2015[2] and the first paper for the study was published in 2017.[1] The STRONG cohort represents the largest cohort of transgender people studied to date and the first such large-scale study conducted in the United States.[2]

STRONG has published papers assessing transgender population size and demographics,[3] agreement between electronic medical records and self-reported gender identity,[4] gender dysphoria and mental health,[5][6] suicidality,[7] "passing" and mental health,[8] progression of gender dysphoria in transgender youth,[9] hematological parameters,[10] liver parameters,[11] acne risk,[12][13] psoriasis risk,[14] cardiovascular health,[15][16] diabetes risk,[17][18] and cancer risk.[19]

See also

  • European Network for the Investigation of Gender Incongruence (ENIGI)

References

  1. ↑ 1.0 1.1 1.2 "Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people". BMJ Open 7 (12): e018121. December 2017. doi:10.1136/bmjopen-2017-018121. PMID 29284718. 
  2. ↑ 2.0 2.1 Quinn VP, Becerra TA, Gillespie T, Hunkeler E, Baird T, Baisch NM, Owen-Smith A, Roblin D, Stephenson R, Tangpricha V, Valentine C, Goodman M. Embedding Patients, Providers, and Community Stakeholders in Research to Improve Transgender Health. J Patient Cent Res Rev 2015;2:114–115. http://dx.doi.org/10.17294/2330-0698.1137
  3. ↑ "Changes in Size and Demographic Composition of Transgender and Gender Non-Binary Population Receiving Care at Integrated Health Systems". Endocr Pract 27 (5): 390–395. May 2021. doi:10.1016/j.eprac.2020.11.016. PMID 33678315. 
  4. ↑ "Agreement between medical records and self-reports: Implications for transgender health research". Rev Endocr Metab Disord 19 (3): 263–269. September 2018. doi:10.1007/s11154-018-9461-4. PMID 30219985. 
  5. ↑ "Association Between Gender Confirmation Treatments and Perceived Gender Congruence, Body Image Satisfaction, and Mental Health in a Cohort of Transgender Individuals". J Sex Med 15 (4): 591–600. April 2018. doi:10.1016/j.jsxm.2018.01.017. PMID 29463478. 
  6. ↑ "Mental Health of Transgender and Gender Nonconforming Youth Compared With Their Peers". Pediatrics 141 (5). May 2018. doi:10.1542/peds.2017-3845. PMID 29661941. 
  7. ↑ "Suicide Attempts Among a Cohort of Transgender and Gender Diverse People". Am J Prev Med 59 (4): 570–577. October 2020. doi:10.1016/j.amepre.2020.03.026. PMID 32798005. 
  8. ↑ "Visual Conformity With Affirmed Gender or "Passing": Its Distribution and Association With Depression and Anxiety in a Cohort of Transgender People". J Sex Med 17 (10): 2084–2092. October 2020. doi:10.1016/j.jsxm.2020.07.019. PMID 32807706. 
  9. ↑ "Progression of Gender Dysphoria in Children and Adolescents: A Longitudinal Study". Pediatrics 148 (1). July 2021. doi:10.1542/peds.2020-027722. PMID 34099504. 
  10. ↑ "Longitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy". J Endocr Soc 4 (11): bvaa119. November 2020. doi:10.1210/jendso/bvaa119. PMID 33834151. 
  11. ↑ "Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy". J Sex Med 18 (9): 1662–1675. September 2021. doi:10.1016/j.jsxm.2021.06.011. PMID 34366264. 
  12. ↑ "Prevalence of moderate to severe acne in transgender adults: A cross-sectional survey". J Am Acad Dermatol 83 (5): 1450–1452. November 2020. doi:10.1016/j.jaad.2020.02.053. PMID 32109538. 
  13. ↑ "Moderate-to-Severe Acne and Mental Health Symptoms in Transmasculine Persons Who Have Received Testosterone". JAMA Dermatol 157 (3): 344–346. March 2021. doi:10.1001/jamadermatol.2020.5353. PMID 33471032. 
  14. ↑ Braun, Hayley; Thompson, Elaine C.; Zhang, Qi; Tangpricha, Vin; Goodman, Michael; Yeung, Howa (28 March 2022). "Prevalence of Psoriasis and Perceived Association with Hormone Therapy in Transgender Adults". Transgender Health 8 (4): 396–399. doi:10.1089/trgh.2021.0104. ISSN 2688-4887. PMID 37525834. 
  15. ↑ "Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study". Ann Intern Med 169 (4): 205–213. August 2018. doi:10.7326/M17-2785. PMID 29987313. 
  16. ↑ "Cross-Sex Hormones and Acute Cardiovascular Events in Transgender Persons". Ann Intern Med 170 (2): 143. January 2019. doi:10.7326/L18-0564. PMID 30641565. 
  17. ↑ "Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort". J Clin Endocrinol Metab 107 (4): e1549–e1557. March 2022. doi:10.1210/clinem/dgab832. PMID 34850912. 
  18. ↑ "Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons". J Clin Endocrinol Metab 107 (6): e2632–e2633. May 2022. doi:10.1210/clinem/dgac060. PMID 35106582. 
  19. ↑ "Cohort study of cancer risk among insured transgender people". Ann Epidemiol 27 (8): 499–501. August 2017. doi:10.1016/j.annepidem.2017.07.007. PMID 28780974. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Study_of_Transition,_Outcomes,_and_Gender&oldid=3360697"